Jones Financial Companies Lllp raised its stake in Sanofi (NASDAQ:SNY – Free Report) by 55.0% during the 4th quarter, ...

Patients with asthma who used depemokimab tolerated treatment well while experiencing reductions in rates of clinically ...

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itch Dupixent also significantly ...

Patients with chronic spontaneous urticaria that was not controlled with H1 antihistamines experienced improvements in itch and urticaria activity with dupilumab, according to a poster presented here.

Recent refinements to a multiphase approach to delusional infestations make this treatment protocol effective even within a ...

Half of patients who used delgocitinib cream for chronic hand eczema had a profound response, and a third who stopped ...

Matthew Bedrossian is general counsel at Evidation - a company that measures health in everyday life and enables anyone to ...

Key Innovations and 5 Companies to Watch in 2025Artificial intelligence is everywhere in 2024, changing industries and ...

Sanofi stock is surging with a Golden Cross formation and promising Dupixent results. With FDA review and potential approval, investors are excited.

One of the most highly anticipated FDA decisions this month is for Alnylam Pharmaceuticals, which is seeking to expand the ...

Attorney General Aaron M. Frey announced a settlement agreement with Sanofi-Aventis U.S. LLC after scrutiny over the ...